Literature DB >> 24688023

CTLA-4 is expressed by activated mouse NK cells and inhibits NK Cell IFN-γ production in response to mature dendritic cells.

Ana Stojanovic1, Nathalie Fiegler, Monika Brunner-Weinzierl, Adelheid Cerwenka.   

Abstract

NK cells express an array of activating and inhibitory receptors that determine NK cell responses upon triggering by cognate ligands. Although activating NK cell receptors recognize mainly ligands expressed by stressed, virus-infected, or transformed cells, most inhibitory receptors engage MHC class I, preventing NK cell activation in response to healthy cells. In this study, we provide insight into the regulation and function of additional receptors involved in mouse NK cell responses: CTLA-4 and CD28. CTLA-4 and CD28 engage the same ligands, B7-1 and B7-2, which are primarily expressed by APCs, such as dendritic cells. Our data demonstrate that activation of mouse NK cells with IL-2 induces the expression of CTLA-4 and upregulates CD28. CTLA-4 expression in IL-2-expanded NK cells was further up- or downregulated by IL-12 or TGF-β, respectively. Using gene-deficient NK cells, we show that CD28 induces, and CTLA-4 inhibits, IFN-γ release by NK cells upon engagement by the recombinant ligand, B7-1, or upon coculture with mature dendritic cells. Notably, we show that mouse NK cells infiltrating solid tumors express CD28 and CTLA-4 and respond to stimulation with recombinant B7-1, suggesting that the NK cell responses mediated by the CD28/CTLA-4:B7-1/B7-2 system could be of importance during malignant disease. Accordingly, our study might have implications for immunotherapy of cancer based on blocking anti-CTLA-4 mAbs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24688023     DOI: 10.4049/jimmunol.1302091

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.

Authors:  Emilio Sanseviero; Erin M O'Brien; Jenna R Karras; Tamer B Shabaneh; Bulent Arman Aksoy; Wei Xu; Cathy Zheng; Xiangfan Yin; Xiaowei Xu; Giorgos C Karakousis; Ravi K Amaravadi; Brian Nam; Mary Jo Turk; Jeff Hammerbacher; Mark P Rubinstein; Lynn M Schuchter; Tara C Mitchell; Qin Liu; Erica L Stone
Journal:  Cancer Immunol Res       Date:  2019-06-25       Impact factor: 11.151

Review 2.  Strategies to enhance NK cell function for the treatment of tumors and infections.

Authors:  Jacquelyn Freund-Brown; Leilani Chirino; Taku Kambayashi
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

3.  Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma.

Authors:  Bethany Mundy-Bosse; Nathan Denlinger; Eric McLaughlin; Nitin Chakravarti; Susan Hwang; Li Chen; Hsiaoyin Charlene Mao; David Kline; Youssef Youssef; Rebecca Kohnken; Dean Anthony Lee; Gerard Lozanski; Aharon G Freud; Pierluigi Porcu; Basem William; Michael A Caligiuri; Anjali Mishra
Journal:  Blood Adv       Date:  2018-08-14

4.  Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.

Authors:  Joy Hsu; Jonathan J Hodgins; Malvika Marathe; Chris J Nicolai; Marie-Claude Bourgeois-Daigneault; Troy N Trevino; Camillia S Azimi; Amit K Scheer; Haley E Randolph; Thornton W Thompson; Lily Zhang; Alexandre Iannello; Nikhita Mathur; Karen E Jardine; Georgia A Kirn; John C Bell; Michael W McBurney; David H Raulet; Michele Ardolino
Journal:  J Clin Invest       Date:  2018-09-10       Impact factor: 14.808

Review 5.  NK cells and cancer: you can teach innate cells new tricks.

Authors:  Maelig G Morvan; Lewis L Lanier
Journal:  Nat Rev Cancer       Date:  2016-01       Impact factor: 60.716

6.  TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer.

Authors:  Alexandre Ivagnès; Meriem Messaoudene; Gautier Stoll; Bertrand Routy; Aurélie Fluckiger; Takahiro Yamazaki; Kristina Iribarren; Connie P M Duong; Laetitia Fend; Anne Caignard; Isabelle Cremer; Axel LeCesne; Julien Adam; Charles Honoré; Olivier Mir; Loïc Chaigneau; Anne Berger; Pierre Validire; Christos Christidis; Valérie Le Brun-Ly; Mark J Smyth; Xavier Mariette; Benoît L Salomon; Guido Kroemer; Sylvie Rusakiewicz; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2017-10-11       Impact factor: 8.110

Review 7.  Roles of cytotoxic and helper innate lymphoid cells in cancer.

Authors:  Camille Guillerey
Journal:  Mamm Genome       Date:  2018-09-03       Impact factor: 2.957

Review 8.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

9.  Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7.

Authors:  Matthew M Halpert; Vanaja Konduri; Dan Liang; Yunyu Chen; James B Wing; Silke Paust; Jonathan M Levitt; William K Decker
Journal:  Stem Cells Dev       Date:  2016-05-02       Impact factor: 3.272

Review 10.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.